Intellectual Property Law Updates Worldwide
60 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by PatentAttorney_Delhi_Intellectual_Property_Law_Firm
Scoop.it!

Patent Filing Procedures in India

In India, the first and foremost step to protect the invention/ innovation/ idea is to file the patent application before the Indian Patent Office. 
The patent application can filed by submitting a few patent forms namely Form 1, Form 2, Form 3 and Form 5. Currently, patent forms in India can be submitted online as well as offline.  

PatentAttorney_Delhi_Intellectual_Property_Law_Firm's insight:

Are you an individual researcher or inventor with a new or improved innovation, idea, invention, product, or method, process or do you have a business and have coined a new name, slogan, or design you wish to protect by filing for trademark or design protection in India? 

more...
No comment yet.
Scooped by PatentAttorney_Delhi_Intellectual_Property_Law_Firm
Scoop.it!

Latest mhealth Trends for Mobile App Developers to Watch in Mobile Health

Latest mhealth Trends for Mobile App Developers to Watch in Mobile Health | Intellectual Property Law Updates Worldwide | Scoop.it
Mobile Applications Medical and Healthcare Sector, mHealth Applications: 
Conventional solutions to address health related problems worldwide have been rising enormously. In many cases the healthcare providers are not able to provide treatment because of accessibility problem in many regions. Therefore, in current scenario, the need of the hour is innovation from latest technologies and this is where Internet based innovation from digital and social media comes into play.
PatentAttorney_Delhi_Intellectual_Property_Law_Firm's insight:

Recently, I shared insights into how digital health innovations are revolutionizing the medical and healthcare industry. Main points covered in the article:

Socialization of healthcare via mobile (mHealth)Exemplary patent scenarioEthical and legal issues
more...
No comment yet.
Scooped by PatentAttorney_Delhi_Intellectual_Property_Law_Firm
Scoop.it!

Antares Pharma Inc (ATRS) Receives Reissued United States Patents RE44846 & RE44847 for OTREXUP

Antares Pharma Inc (ATRS) Receives Reissued United States Patents RE44846 & RE44847 for OTREXUP | Intellectual Property Law Updates Worldwide | Scoop.it

U.S. Patents RE44846 and RE44847 are reissued versions of U.S. Patents  7,776,015 and  7,744,582. United States Patent RE44847 titled "Needle assisted jet injector" granted to Antares Pharma, Inc was published by USPTO on 15th April, 2014. The said patent claims a method of operating an injection device containing a medicament-containing fluid chamber, said injector device having a distal and a proximal end, and a needle guard a portion of which is located within the distal end of the injection device, said needle guard having an extended position and a retracted position, and an injecting needle having an axial opening, said method comprising the steps of:
-applying the distal end of the injection device to an injection site so as to gently urge the needle guard to move proximally further into the distal end of the injection device to the retracted position thereby activating a stored energy generating mechanical member to pressurize the medicament-containing fluid chamber and to eject the medicament from the injecting needle into the injection site;

-removing the distal end of the injection device from the injection site, wherein the needle guard moves from the retracted position to the extended position; and

wherein the pressure in the medicament-containing fluid chamber is sufficient to eject the medicament through the injecting needle at a rate of at least 0.02 ml in 2.75 seconds.
The overall Antares patent portfolio coverage exemplifies the Company’s IP strategy of obtaining patents that are generally directed toward devices, combination products and methods for delivering injectable drugs, which the Company has earned on its filed inventions.


What is a reissue patent application?
A reissue patent application is filed post-grant to correct an error in an
issued patent where the error renders the patent wholly or partially
inoperable or invalid. The procedure is codified in 35 U.S.C. § 251:
The USPTO director, upon request by the patentee, will correct errors in
the patent and reissue the new amended patent. The term of the reissue
patent will be the remaining unexpired term of the original patent,
and the reissued patent cannot contain new matter. The reissue must be for the same invention.

more...
No comment yet.
Scooped by PatentAttorney_Delhi_Intellectual_Property_Law_Firm
Scoop.it!

Boeing, Abbott, & Honeywell support India's Intellectual Property Rights regime

Boeing, Abbott, & Honeywell support India's Intellectual Property Rights regime | Intellectual Property Law Updates Worldwide | Scoop.it
Three major US cos - Boeing, Abbott and Honeywell - have come in support of India's IPR regime, which has come under attack by American pharma sector for violations of global norms.
PatentAttorney_Delhi_Intellectual_Property_Law_Firm's insight:

Recently, India is under attack by American pharma sector for alleged violations of global IPR norms.  
However, Boeing leader in aviation sector has said that India has a strong legal framework to protect IPR rights.

In another statement, pharma company Abbott has stated that it is not currently facing any significant challenges with respect to intellectual property protection in India. 

India's patent act and especially section 3d of the Indian Patent Act, stops ever-greening of pharmaceutical molecules.  

 
more...
No comment yet.
Scooped by PatentAttorney_Delhi_Intellectual_Property_Law_Firm
Scoop.it!

ViiV Healthcare grants licence of its HIV medicine Tivicay (dolutegravir) to Medicines Patent Pool MPP to improve access

ViiV Healthcare grants licence of its HIV medicine Tivicay (dolutegravir) to Medicines Patent Pool MPP to improve access | Intellectual Property Law Updates Worldwide | Scoop.it

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline , US drugmaker Pfizer and Japanese drug major Shionogi has announced new collaborations to increase access to its HIV medicine Tivicay (dolutegravir).
The collaboration with Medicines Patent Pool MPP includes two approaches to improve access for adults living with HIV in the developing world a royalty-free voluntary licence in all least-developed, all low-income and all sub-Saharan African countries; and for specific middle-income countries including India, ViiV Healthcare has established the first MPP licence with a tiered royalty structure, where a small percentage of the sale price is paid based on the Gross Domestic Product (GDP) of the specific country.


more...
No comment yet.
Scooped by PatentAttorney_Delhi_Intellectual_Property_Law_Firm
Scoop.it!

The Medicines Company sued Aurobindo Pharma in US court for alleged infringement of patents of its heart drug Angiomax

The Medicines Company sued Aurobindo Pharma in US court for alleged infringement of patents of its heart drug Angiomax | Intellectual Property Law Updates Worldwide | Scoop.it

Recently, Aurobindo Pharma filed for the approval of 250 mg vial of generic Angiomax, chemically known as bivalirudin with the US Food and Drug Administration. 
The abbreviated new drug application (ANDA) infringes on two patents held by the Medicines Company as stated in the lawsuit US 7598343 and US 7582727.
The 727 patent was issued on September 2009 and the 343 patent was allowed in October 2009. The patent relates to pharmaceutical formulations comprising bivalirudin as the active ingredient, and a method of preparing the pharmaceutical formulation(s). 

PatentAttorney_Delhi_Intellectual_Property_Law_Firm's insight:
United States Patent 7598343 titled "Pharmaceutical formulations of bivalirudin and processes of making the same" claims pharmaceutical batches of a drug product comprising bivalirudin (SEQ ID NO: 1) and mannitol for use as an anticoagulant in a subject in need thereof, said batches prepared by a compounding process comprising: (i) dissolving bivalirudin in a solvent to form a first solution; (ii) efficiently mixing a pH-adjusting solution with the first solution to form a second solution, wherein the pH-adjusting solution comprises a pH-adjusting solution solvent; and (iii) removing the solvent and pH-adjusting solution solvent from the second solution; wherein the batches have a pH adjusted by a sodium hydroxide, said pH is about 5-6 when reconstituted in an aqueous solution for injection, and wherein the batches have a maximum reconstitution time that does not exceed about 42 seconds and a maximum total impurity level that does not exceed about 2% as measured by HPLC.
more...
No comment yet.